Acute myeloid leukaemia (AML) is predominantly a disease of palliative treatment with oral drugs or low-dose subcutaneous the elderly but such patients are not always appropriate candicytosine. There is clearly a requirement for alternative, moderdates for intensive intravenous (i.v.) based treatment regimens.
study was approved by the local ethics committee and all patients gave fully informed consent.
Morphological diagnosis of AML was made on RomanovIntroduction sky-stained blood and bone marrow smears and the diagnosis confirmed by appropriate cytochemical staining and whenAcute myeloid leukaemia (AML) is a disease of the elderly. In ever possible immunophenotyping of blasts for myeloidpopulation-based studies over 50% of patients with AML are associated antigens CD13, CD14 and CD33. aged 55 or over. 1, 2 The number of cases presenting in the eldPatients were entered into this study during the period Januerly will continue to increase as the population ages. If the ary 1994-December 1995. Presenting details including age, age-specific incidence remains static, by the year 2031 this sex, performance status at presentation, 11 presenting WCC, will result in an increase of almost 40% in cases of AML aged FAB subtype, 12-14 chromosomal analysis and presence or 60 years and over. 3 The best approach to treatment remains absence of pre-existing trilineage myelodysplasia were colcontroversial. Age alone is one of the strongest adverse proglected. Toxicity was assessed using the WHO classification 11 nostic factors for AML. Aggressive chemotherapy is poorly and survival analysis was done according to the Kaplantolerated by most elderly patients 4 although a small minority Meier methods. 15 of patients achieve a prolonged remission with this Patients received one to four courses of chemotherapy conapproach.
5-8 However, in most studies of elderly patients with sisting of idarubicin 30 mg/m 2 and etoposide 80 mg/m 2 once AML, the long-term results are unsatisfactory (with long-term daily for 3 consecutive days. Courses were given every 3 survival even in those given intensive treatment at less than weeks and it was recommended that patients who achieved 20%) even in those studies which have good CR rates. 9 remission received two courses of the same therapy as conThere is little doubt that most patients are either considered solidation treatment but this was given at the discretion of the unsuitable for such intensive chemotherapy or have AML with treating physician. No patients received growth factor support. such poor prognostic features that cure is unlikely even with intensive treatment. In the past, such patients have been given Results Presenting details are shown in Table 1 . Two patients died survival, event-free survival and cause of death are shown in Table 3 . It is noteworthy that after initial treatment, eight out before they received treatment having already given consent and one patient subsequently changed his mind having given of 21 subsequent courses were given entirely on an outpatient basis. consent, and refused trial chemotherapy opting for less intensive treatment. Therefore 25 patients received treatment, 11
During
Eleven patients received only one course of chemotherapy. In only one case (patient 15) was this due to the patient refusreceived one course, eight received two courses and six received three to four courses of chemotherapy. There was no ing to take any further therapy. A further patient (patient 2) had an improvement in her general condition and then serious (WHO classification grade 3-4) non-haematological toxicity and the regimen was well tolerated. The haematologireceived further treatment with an intensive i.v. regimen. Of the remaining nine, two patients had resistant AML, five cal toxicity of this treatment regimen, including duration of cytopenia, transfusion requirements, number of days spent in died of a bleeding diathesis (four GI bleeds, one CVA (cerebrovascular accident)) and one had a perforated bowel hospital and days on antibiotics, is shown in Table 2 .
The number of courses of treatment, response to treatment, before the response to treatment could be assessed. A further patient with normal blood counts (patient 23) in first CR after Discussion one course of chemotherapy died of a CVA immediately prior to a planned course of consolidation chemotherapy.
The optimal treatment of elderly patients with AML is the subOf the 11 patients who responded to treatment, nine achieved ject of much discussion and with the increasing numbers of CR and two a good partial response. This represents a response elderly people within the population it is an increasingly comrate of 39% and CR rate of 32% for the whole cohort and a mon dilemma. In a minority of very fit older patients with response rate of 44% and CR rate of 36% for patients who actugood prognostic features there is an important role for intenally commenced treatment. The median survival for the whole sive chemotherapy regimens. When an elderly patient cohort was 3 months (range 1 day-Ͼ34 months) but for those presents with AML, their age, per se, should not be the decidwho achieved a CR it is 9 months (range 1-Ͼ34 months). Six ing factor in treatment allocation. A careful analysis of other patients who achieved CR remain alive, five in first CR and one prognostic factors (such as performance status, FAB subtype, who relapsed and went into second CR after two further courses cytogenetics, evidence of pre-existing myelodysplasia and of treatment. The survival curves for the whole cohort and for assessment of other organ function) should be performed and responding patients are shown in Figure 1 . treatment decided on an individual basis. No patient should be denied the chance of curative treatment because of their age alone. However, for the majority of elderly patients, intensive i.v. regimens are considered inappropriate as they are too toxic and carry little prospect of cure. 16, 17 For instance, less than 10% of patients over the age of 60 in the UK were entered into the MRC AML8 trial and the proportion fell dramatically as the age of the patient rose. A moderately intensive, effective but less toxic oral chemotherapy regimen which can be given either on an out-patient or in-patient basis would be a useful addition to the therapeutic options for elderly patients with AML, considered unsuitable for more intensive regimens.
The advent of iradrubicin, an anthracycline which can be given orally has made such an approach possible. The bioavailability of idarubicin, and its metabolite idarubicinol, after oral administration is good even in the elderly. 18 Idarubicin, when given intravenously, is an extremely effective treatment in AML in younger patients. 19 Others have demonstrated bicin alone, and a similar CR rate using idarubicin in combi-3 Johnson PRE, Liu Yin JA. Clinical annotation -acute myeloid leunation with low-dose Ara-C. 21 Ruutu and colleagues 22 kaemia in the elderly: biology and treatment. Br J Haematol 1993;  observed a complete remission rate of 60% (24% after course 83: 1-6.
1) when using a combination etoposide, idarubicin and 6-
